Vantrexa · NSCLC · United Kingdom · Thoracic medical oncologist · captured by Rachel Adeyemi on 18 Jun 2026 · reviewed by Dr. Priya Raman on 20 Jun 2026
Verbatim as captured; never edited
Consultant at the Royal Marsden asked what the recommended approach is after progression on vantrelimab — platinum doublet, docetaxel-based, or re-challenge with a checkpoint inhibitor. He noted the UK NSCLC network is drafting a pathway document and will default to docetaxel unless evidence supports otherwise.
Human-approved by Dr. Priya Raman on 20 Jun 2026
UK network drafting post-progression pathway; will default to docetaxel absent sequencing evidence. Time-sensitive opportunity to inform pathway with available data.
helixor-private-llm-2026.05 · generated 18 Jun 2026, 17:05 UTC
AI summary
UK consultant requests post-progression sequencing guidance; national pathway defaulting to docetaxel.
Source spans used by the model
Consultant at the Royal Marsden asked what the recommended approach is after progression on vantrelimab — platinum doublet, docetaxel-based, or re-challenge with a checkpoint inhibitor. He noted the UK NSCLC network is drafting a pathway document and will default to docetaxel unless evidence supports otherwise.
| Field | AI suggestion | Final (human-approved) |
|---|---|---|
| Category | Treatment pathway | Treatment pathway |
| Function | Medical Affairs | Medical Affairs |
| Priority | High | Critical |
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 4 | 20% | 16.0 |
| Strategic alignment | 5 | 20% | 20.0 |
| Scientific importance | 4 | 15% | 12.0 |
| Urgency | 5 | 15% | 15.0 |
| Novelty | 2 | 10% | 4.0 |
| Actionability | 5 | 10% | 10.0 |
| Confidence | 4 | 5% | 4.0 |
| Breadth of occurrence | 5 | 5% | 5.0 |
| Total | Critical 86 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
18 Jun 2026 · Dr. Liam Quinn, Royal Marsden · MSL Rachel Adeyemi
Insight
Reviewed 20 Jun 2026 by Dr. Priya Raman
Medical Affairs · Dr. Priya Raman · due 15 Oct 2026 · In progress
Publication project · David Chen · In progress
Decision
Outcome
Publication · INI-0103
Closure